All In Biotech

Drug Trial Radar · NCT05056727

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on CKD Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,112 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,112

Actual

Start

Sep 30, 2021

Primary completion

Feb 7, 2024

Study completion Feb 7, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC), as adjunct to ACEi/ARB therapy (lisinopril or valsartan), on slowing CKD progression (assessed as the reduction in participant's glomerular filtration rate \[eGFR\] decline over time) in participants with hyperkalaemia or at high risk of hyperkalaemia.

Conditions

  • Renal Insufficiency, Chronic
  • Hyperkalemia

Interventions

  • Sodium Zirconium Cyclosilicate (SZC)Drug

    Powder for oral suspension in a sachet. Unit dose strength: 5 or 10 g SZC. Single dose will consist of 1-3 sachets. During Initiation Phase: * S-K \> 5 to ≤ 6.5 mmol/L (measured by L-Lab): Single dose contains 10 g SZC that should be suspended in 45 mL of water. The 10 g SZC single dose should be administered three times daily for up to 72 hours until normokalaemic (S-K 3.5-5.0 mmol/L); the total daily dose is 30 g SZC. * S-K ≥ 3.5 to ≤ 5 mmol/L (measured by L-Lab): Single dose contains 5 g SZC that should be suspended in 45 mL of water and administered once daily for 48 hours. During Run-in and Maintenance Phases: \- Single dose contains 5 g SZC administered every other day or 5, 10, or 15 g SZC administered once daily that should be suspended in 45 mL of water.

  • PlaceboDrug

    Powder for oral suspension in a sachet. Placebo to match 5 or 10 g. Single dose will consist of 1-3 sachets. During Maintenance Phase: \- Single dose contains 5 g placebo administered every other day or 5, 10, or 15 g placebo administered once daily that should be suspended in 45 mL of water.

  • LisinoprilDrug

    Tablet for oral administration. Unit dose strength: 2.5, 5, 10 or 20 mg. Dosage level: 5, 10, 20, or 40 mg administered once daily.

  • ValsartanDrug

    Tablet or capsule for oral administration. Unit dose strength: 40, 80 or 160 mg. Dosage level: 40, 80, 160, or 320 mg administered once daily.

  • IrbesartanDrug

    Tablet for oral administration. Unit dose strength: 75, 150 or 300 mg. Dosage level: 75, 150, or 300 mg administered once daily. The study is designed to use valsartan as the selected ARB therapy adjunct to SZC. However, if an actual shortage of valsartan in a local market jeopardises the ability of participants to enter or continue in the study, valsartan can be temporarily substituted with irbesartan until the shortage of valsartan is resolved.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total eGFR Slope (Coprimary Analysis #1)Time frame: Baseline (Maintenance phase) to visit 17 (week 69)
  2. Chronic eGFR Slope (Coprimary Analysis #2)Time frame: 12 weeks to visit 17 (week 69)

Locations

276 sites in 21 countries. Site status is shown where the registry gives one.

  • Research Site

    Surprise, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Canyon Country, California

  • Research Site

    Chula Vista, California

  • Research Site

    Northridge, California

  • Research Site

    San Dimas, California

  • Research Site

    South Gate, California

  • Research Site

    Tarzana, California

  • Research Site

    Denver, Colorado

  • Research Site

    Boynton Beach, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Lauderdale Lakes, Florida

  • Research Site

    Ocoee, Florida

  • Research Site

    Temple Terrace, Florida

  • Research Site

    Nampa, Idaho

  • Research Site

    Chicago, Illinois

  • Research Site

    Oak Brook, Illinois

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Louisville, Kentucky

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    Flint, Michigan

  • Research Site

    Saint Clair Shores, Michigan

  • Research Site

    Columbia, Missouri

  • Research Site

    Kansas City, Missouri

  • Research Site

    Albuquerque, New Mexico

  • Research Site

    Albany, New York

  • Research Site

    Great Neck, New York

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Bethlehem, Pennsylvania

  • Research Site

    Chester, Pennsylvania

  • Research Site

    Columbia, South Carolina

  • Research Site

    Orangeburg, South Carolina

  • Research Site

    Chattanooga, Tennessee

  • Research Site

    Arlington, Texas

  • Research Site

    Fort Worth, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Houston, Texas

Showing 40 of 276 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.